Shroff RT, et al. - In this phase 2 trial including 60 patients, researchers examined if nab-paclitaxel added to gemcitabine-cisplatin therapy can prolong progression-free survival in patients with advanced biliary tract cancers vs historical controls treated with gemcitabine-cisplatin alone. In an intention-to-treat analysis, median progression-free survival was 11.8 months and median overall survival was 19.2 months when nab-paclitaxel plus gemcitabine-cisplatin was administered with the partial response rate of 45% and the disease control rate of 84%. Advanced biliary tract cancers treated with nab-paclitaxel plus gemcitabine-cisplatin thus may extend survival vs treatment with gemcitabine-cisplatin alone.